[Form 4] Imax Corp Insider Trading Activity
Kenneth Ian Weissman, IMAX Corp executive (Deputy General Counsel, Corporate Secretary & Chief Compliance Officer), reported option exercise and subsequent share sales on 08/14/2025. He exercised 7,072 stock options with an exercise price of $22.49 (options issued in 2019, expiring 03/07/2026) converting them into 7,072 common shares. The filing shows two dispositions the same day: sale of 7,072 shares at $25.6707 and sale of 8,000 shares at $25.6272.
Ownership changed from an opening balance of 34,133 common shares to a post-transaction balance of 26,133 common shares. The filing notes Mr. Weissman retains 17,021 restricted share units outstanding and that the exercised options were vested in installments between 2020 and 2023.
- Options exercised at $22.49 and sold at higher prices (~$25.63–$25.67), indicating a realized gain before taxes and fees
- Clear disclosure of vesting schedule and option expiration (03/07/2026) improves transparency for investors
- Net reduction in common shares from 34,133 to 26,133, representing decreased insider ownership in absolute terms
- No explicit 10b5-1 plan referenced in the filing, so sales appear to be discretionary rather than under a pre-established trading plan
Insights
TL;DR: Routine option exercise followed by same-day sales; small net reduction in holdings, consistent with typical executive liquidity actions.
The report documents conversion of 7,072 options at a $22.49 exercise price and immediate sales at roughly $25.63–$25.67, implying a per-share spread realized before fees and taxes. The transactions appear non-controversial and do not indicate new compensation terms or extraordinary transfers. Remaining common shares total 26,133 with 17,021 RSUs outstanding, leaving material ownership intact relative to routine insider activity.
TL;DR: Disclosure follows Rule 16 reporting norms; vesting schedule and option expiry are clearly stated.
The Form 4 discloses exercisable option tranches (1,414; 1,768; 1,768; 2,122) and the 03/07/2026 expiration, which helps trace long-term incentive timing. Sales executed the same day as exercise may reflect pre-arranged liquidity or tax-driven decisions; the filing does not state a 10b5-1 plan. No departures, grants, or other governance events are reported.